Principia Wealth Advisory’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.75K Buy
55
+1
+2% +$89 ﹤0.01% 388
2026
Q2
$4.88K Buy
54
+3
+6% +$251 ﹤0.01% 376
2026
Q1
$4.08K Buy
51
+13
+34% +$1.07K ﹤0.01% 343
2025
Q4
$3.24K Sell
38
-475
-93% -$39K ﹤0.01% 346
2025
Q3
$39.9K Buy
513
+487
+1,873% +$38.1K 0.03% 130
2025
Q2
$2.03K Buy
26
+15
+136% +$1.12K ﹤0.01% 381
2025
Q1
$769 Sell
11
-5
-31% -$358 ﹤0.01% 464
2024
Q4
$1.18K Buy
+16
New +$1.12K ﹤0.01% 332

Other funds holding EW

Principia Wealth Advisory's EW Position: Q3 2026 in Review

Principia Wealth Advisory increased its Edwards Lifesciences (EW) stake by 1.9% in Q3 2026, buying an estimated $89 and bringing the position to 55 shares worth $4.75K. The position accounts for ﹤0.01% of the portfolio, ranked #388.

Principia Wealth Advisory first reported a position in EW in Q4 2024 and has held it in 8 quarters since. The position peaked at $39.9K in Q3 2025. 1,345 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Principia Wealth Advisory held 55 shares of Edwards Lifesciences worth $4.75K as of Q3 2026.
  • Principia Wealth Advisory bought 1 Edwards Lifesciences share in Q3 2026, an estimated $89.
  • Edwards Lifesciences made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q3 2026, its #388 holding.
  • Principia Wealth Advisory first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 8 quarters since.
  • Principia Wealth Advisory's Edwards Lifesciences position peaked at $39.9K in Q3 2025.
  • 1,345 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Principia Wealth Advisory's 13F filing for Q3 2026, filed 12 Nov 2026.